Cargando…
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
BACKGROUND: Few data have been published on the clinical and histopathological characteristics of advanced non-small–cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779294/ https://www.ncbi.nlm.nih.gov/pubmed/33408480 http://dx.doi.org/10.2147/OTT.S288825 |
_version_ | 1783631304455094272 |
---|---|
author | Auliac, Jean-Bernard Guisier, Florian Bizieux, Acya Assouline, Pascal Bernardini, Marie Lamy, Régine Justeau, Grégoire François, Geraldine Damotte, Diane Chouaïd, Christos |
author_facet | Auliac, Jean-Bernard Guisier, Florian Bizieux, Acya Assouline, Pascal Bernardini, Marie Lamy, Régine Justeau, Grégoire François, Geraldine Damotte, Diane Chouaïd, Christos |
author_sort | Auliac, Jean-Bernard |
collection | PubMed |
description | BACKGROUND: Few data have been published on the clinical and histopathological characteristics of advanced non-small–cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown. This study was undertaken to prospectively assess the prognostic value of tumor-cell (TC) and immune-cell (IC) PD-L1 expressions for advanced NSCLC patients. METHODS: It was a prospective, multicenter study on advanced NSCLC patients, with performance status 0/1, scheduled, consecutively, to receive first-line platin-based chemotherapy. PD-L1 expression was determined immunochemically (Dako Autostainer and monoclonal antibody 22C3) and its impact on progression-free survival (PFS) and overall survival (OS) assessed. RESULTS: Among 198 patients screened in 19 centers, 140 were included median age: 66.5 ± 10 years; 76.4% men; 79.3% Caucasians; 10.7% nonsmokers; 63.6% adenocarcinomas; <1%, 1–50% and ≥50% TC PD-L1–expression rates were 47.1%, 25.7% and 27.2% of patients, respectively; respective null, intermediate and high rates on ICs were 35.7%, 38.6% and 25.7%. Second- and third-line chemotherapies were administered to 58.6% and 26.4% of the patients, respectively. None received immunotherapy. First-, second- and third-line median (95% CI) PFS lasted 4.6 (3.6–5.2), 3.7 (2.3–4.7) and 2.2 (1.5–4.3) months, respectively; median OS was 16.9 (11.4–19.9) months. No significant PFS and OS differences were observed according to TC or IC PD-L1 expression. CONCLUSION: According to the results of this prospective, multicenter study, neither TC nor IC PD-L1 expression appears to be prognostic for chemotherapy-managed advanced NSCLC patients. |
format | Online Article Text |
id | pubmed-7779294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77792942021-01-05 Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study) Auliac, Jean-Bernard Guisier, Florian Bizieux, Acya Assouline, Pascal Bernardini, Marie Lamy, Régine Justeau, Grégoire François, Geraldine Damotte, Diane Chouaïd, Christos Onco Targets Ther Clinical Trial Report BACKGROUND: Few data have been published on the clinical and histopathological characteristics of advanced non-small–cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown. This study was undertaken to prospectively assess the prognostic value of tumor-cell (TC) and immune-cell (IC) PD-L1 expressions for advanced NSCLC patients. METHODS: It was a prospective, multicenter study on advanced NSCLC patients, with performance status 0/1, scheduled, consecutively, to receive first-line platin-based chemotherapy. PD-L1 expression was determined immunochemically (Dako Autostainer and monoclonal antibody 22C3) and its impact on progression-free survival (PFS) and overall survival (OS) assessed. RESULTS: Among 198 patients screened in 19 centers, 140 were included median age: 66.5 ± 10 years; 76.4% men; 79.3% Caucasians; 10.7% nonsmokers; 63.6% adenocarcinomas; <1%, 1–50% and ≥50% TC PD-L1–expression rates were 47.1%, 25.7% and 27.2% of patients, respectively; respective null, intermediate and high rates on ICs were 35.7%, 38.6% and 25.7%. Second- and third-line chemotherapies were administered to 58.6% and 26.4% of the patients, respectively. None received immunotherapy. First-, second- and third-line median (95% CI) PFS lasted 4.6 (3.6–5.2), 3.7 (2.3–4.7) and 2.2 (1.5–4.3) months, respectively; median OS was 16.9 (11.4–19.9) months. No significant PFS and OS differences were observed according to TC or IC PD-L1 expression. CONCLUSION: According to the results of this prospective, multicenter study, neither TC nor IC PD-L1 expression appears to be prognostic for chemotherapy-managed advanced NSCLC patients. Dove 2020-12-30 /pmc/articles/PMC7779294/ /pubmed/33408480 http://dx.doi.org/10.2147/OTT.S288825 Text en © 2020 Auliac et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Auliac, Jean-Bernard Guisier, Florian Bizieux, Acya Assouline, Pascal Bernardini, Marie Lamy, Régine Justeau, Grégoire François, Geraldine Damotte, Diane Chouaïd, Christos Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study) |
title | Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study) |
title_full | Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study) |
title_fullStr | Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study) |
title_full_unstemmed | Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study) |
title_short | Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study) |
title_sort | impact of programmed death ligand 1 expression in advanced non-small–cell lung cancer patients, treated by chemotherapy (gfpc 06-2015 study) |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779294/ https://www.ncbi.nlm.nih.gov/pubmed/33408480 http://dx.doi.org/10.2147/OTT.S288825 |
work_keys_str_mv | AT auliacjeanbernard impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study AT guisierflorian impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study AT bizieuxacya impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study AT assoulinepascal impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study AT bernardinimarie impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study AT lamyregine impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study AT justeaugregoire impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study AT francoisgeraldine impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study AT damottediane impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study AT chouaidchristos impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study |